CONMED Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
CONMED Stock Forecast and Price Target
Given the average yearlong price target of $107.50 provided by prominent analysts over the past few months, there is a potential upside of approximately 47.99% from the last closing price in April, 2024 for CONMED's stock if it is reached. This estimation is based on a high estimate of $132.00 and a low estimate of $98.00. Even if you are not interested in CNMD stock, you should still be aware of its competitors.
47.99% Upside
CONMED Fair Value Forecast for 2023 - 2025 - 2030
CONMED's Price has decreased In the last four years, from $79.50 to $0.00 – a 100.00% drop. For the next year, analysts predict that Fair Value will reach $161.93 – an increase of 100.00%. Over the next eight years, experts believe that CONMED's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$147.91 | Buy/Sell | $174.55 | 14.93% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$107.28 | Buy/Sell | $118.92 | 18.38% |
| ISRG Stock Forecast | Intuitive Surgical | Outperform |
13
|
$366.34 | Buy/Sell | $408.45 | 17.38% |
| SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$325.43 | Buy/Sell | $353.16 | 12.62% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.48 | Buy/Sell | $92.47 | 20.16% |
CONMED Revenue Forecast for 2023 - 2025 - 2030
In the last three years, CONMED's Revenue has grown by 44.32%, rising from $862.46M to $1.24B. For the next year, analysts predict that Revenue will reach $1.35B – an increase of 8.83%. Over the next eight years, experts believe that CONMED's Revenue will grow at a rate of 34.06%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$67.33 | Buy/Sell | $70.14 | 8.42% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$234.12 | Buy/Sell | $284.47 | 19.60% |
| ECL Stock Forecast | Ecolab | Hold |
18
|
$218.16 | Buy/Sell | $205.36 | 5.89% |
.jpg)
CONMED Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, CONMED's Dividend per Share has seen a drop from $0.80 to $0.80 – a 0.00% decrease. According to 2 major analysts, CONMED's Dividend per Share will fall by 0.00% in the next year, reaching $0.80. Professionals believe that By 2030, CONMED's Dividend per Share will fall to $0.80– a 0.00% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$85.94 | Buy/Sell | $91.18 | 12.87% |
| WST Stock Forecast | West Pharmaceutical Services | Outperform |
18
|
$372.04 | Buy/Sell | $380.80 | 2.14% |
| RMD Stock Forecast | ResMed Inc | Outperform |
17
|
$178.85 | Buy/Sell | $201.32 | 14.62% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CAH Stock Forecast | Cardinal Health Inc | Hold |
13
|
$108.19 | Buy/Sell | $108.07 | 6.76% |
| ZBH Stock Forecast | Zimmer Biomet Holdings | Hold |
15
|
$119.43 | Buy/Sell | $132.52 | 13.87% |
| 4543 Stock Forecast | Terumo | Outperform |
18
|
¥5.63k | Buy/Sell | ¥4.97k | -9.46% |
CONMED EBITDA Forecast for 2023 - 2025 - 2030
CONMED's EBITDA has seen growth In the last three years, going from $138.30M to $202.99M – a gain of 46.78% In the next year, analysts believe that EBITDA will reach $276.87M – an increase of 36.40%. For the next eight years, the forecast is forEBITDA to grow by 89.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| STE Stock Forecast | STERIS | Outperform |
13
|
$199.51 | Buy/Sell | $238.33 | 19.30% |
| COO Stock Forecast | The Cooper Companies | Outperform |
13
|
$90.42 | Buy/Sell | $391.40 | 21.65% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$75.38 | Buy/Sell | $81.06 | 11.44% |
CONMED EBIT Forecast for 2023 - 2025 - 2030
In the last three years, EBIT for CONMED has grown by 86.36%, going from $70.38M to $131.16M. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $217.91M – an increase of 66.14%. Over the next nine years, experts anticipate that EBIT growth for CONMED will be 150.21%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABMD Stock Forecast | Abiomed | - |
16
|
$377.79 | Buy/Sell | $380.00 | -88.33% |
| 7733 Stock Forecast | Olympus | Outperform |
18
|
¥2.10k | Buy/Sell | ¥2.30k | 14.48% |
| SN. Stock Forecast | Smith & Nephew | Outperform |
18
|
£9.62 | Buy/Sell | £16.09 | 70.58% |
CONMED EPS Price Prediction Forecast for 2023 - 2025 - 2030
CONMED's EPS has decreased In the last four years, from $2.18 to $0.00 – a 100.00% drop. For the next year, analysts predict that EPS will reach $4.44 – an increase of 100.00%. Over the next eight years, experts believe that CONMED's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TFX Stock Forecast | Teleflex Inc | Hold |
13
|
$206.56 | Buy/Sell | $263.46 | 28.29% |
| XRAY Stock Forecast | DENTSPLY SIRONA | Outperform |
17
|
$30.50 | Buy/Sell | $36.00 | 22.30% |
| MMSI Stock Forecast | Merit Medical Systems | Outperform |
14
|
$72.03 | Buy/Sell | $89.25 | 22.87% |
.jpg)